“So you'll see us the capital allocation share repurchase level will come back into greater consideration going forward.”

In context

“erator: Our next question comes from Evan Seigerman with BMO Capital Markets. Evan Seigerman: I really want to touch on capital deployment, specifically when it comes to share repurchases. Dave, I know that, that's been a method that you wanted to employ now with clarity on [indiscernible] and the CAGR post-2028, what other -- what else do you need to see to potentially start buying back shares, especially at these levels? David Denton: Yes, Evan, great question. We always look at our capital allocation strategy of balancing between the 3 options that we have. At the moment, our focus is really on investing in our R&D platform and in business development to drive long-term value. With the development in these court cases, that does give us a bit more confidence in our cash flow over time. So you'll see us the capital allocation share repurchase level will come back into greater consideration going forward. So great question. Something we always look at, and we're always looking to do what's best for the company and shareholders long term. Operator: Our next question comes from Courtney Breen with Bernstein. Courtney Breen: I just wanted to probe a little bit more on [ sigtolimod vedotin ] and positioning in that frontline setting, all comers relative to the Symbiotic-Lung-01 study that you've already started with the PD-1 VEGF. I also note that you've got kind of a Phase I/II running combining these 2 assets. And can you help us contextualize that new Phase III all-comers that you intend to start this year for SV first line and how that may be positioned relative to Symbiotic-Lung-01? Albert Bourla: All right, Chris? Chris Boshoff: Thank you very much for the question. Lung cancer is obviou”